Optic Neuritis Treatment Trial (ONTT)

Status unknownPhase 3MS (type not specified)NCT00000146

What it found

Paper found, not read

A paper reports the results; we have not read it yet. See Papers below.

What was tested

Treatment tested

  • Methylprednisolone

    Glucocorticoid receptor agonist

  • Prednisone

    Glucocorticoid receptor agonist

Who could take part

MS (type not specified) · 18 to 46

Show the full criteria

Inclusion criteria

The major eligibility criteria for enrollment into the ONTT included the following: Age range of 18 to 46 years Acute unilateral optic neuritis with visual symptoms for 8 days or less A relative afferent pupillary defect and a visual field defect in the affected eye No previous episodes of optic neuritis in the affected eye No previous corticosteroid treatment for optic neuritis or multiple sclerosis No systemic disease other than multiple sclerosis that might be the cause of the optic neuritis

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.

Papers

Loading reviews and guidelines…

Related trials

History

    1. Started

      Jul 1988

    Assembled by software from public sources.